cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.29150499.v1
title: Meta-analysis for alterations of IFN-γ, TNF-α and granzyme B levels in vitiligo patients

description: Vitiligo is a chronic autoimmune skin depigmenting condition. IFN-γ, TNF-α and granzyme B play key roles in vitiligo pathogenesis, some findings suggest their roles may be contradictory. We aimed to assess IFN-γ, TNF-α and granzyme B levels in blood and skin of vitiligo patients using a meta-analysis approach. Additionally, we evaluated their association with disease activity. A Meta-analysis was conducted using Review Manager 5.4 software. A total of 55 studies including 3,023 vitiligo patients and 2,534 controls were included in the study. Pooled results from our meta-analysis indicated significantly elevated IFN-γ protein and transcript levels in blood and skin of vitiligo patients (<i>p</i> &lt; 0.05). TNF-α protein levels were also significantly increased in blood and skin of vitiligo patients (<i>p</i> &lt; 0.05). IFN-γ and TNF-α levels were significantly higher in the lesional skin as compared to non-lesional skin (<i>p</i> &lt; 0.05). Furthermore, elevated levels of IFN-γ and TNF-α were observed in patients with active vitiligo (<i>p</i> &lt; 0.05). Additionally, our study suggested a significant increase in granzyme B levels in vitiligo patients (<i>p</i> &lt; 0.05). Overall, the meta-analysis suggests that IFN-γ, TNF-α and granzyme B play a crucial role in vitiligo pathogenesis and progression and may serve as potential therapeutic targets for managing the disease. The PROSPERO registration no. for meta-analysis is CRD42024620274
DOI: 10.6084/m9.figshare.28445421
title: Glucometer versus analyzer: comparable results with negligible clinical risk

description: This study assessed the reliability of Roche Accu-Chek Inform II glucometers in a real-world setting. A retrospective analysis was conducted on 6,695 paired results. Capillary samples were tested using Roche Accu-Chek Inform II glucometers, while venous samples were analyzed using Roche Cobas c503/702 analyzers. Compliance was assessed using modified criteria based on the ISO 15197 guideline and the CLSI EP09-A3 guideline using Passing-Bablok regression analysis, Bland-Altman plots, and Surveillance Error Grid (SEG) analysis. The overall compliance of glucometer results within ±15% or 0.83 mmol/L (15 mg/dL) of the reference method was 81.5%, below the acceptance criterion of 94.6%. SEG analysis showed that 90.3% of the paired results fell within the No-risk zone, with less than 0.001% in the moderate/lower-risk zone. The Emergency Department results indicated 87.8% overall compliance and 92.2% of pairs falling in the No-risk zone. Based on the regression analysis, the glucometer results showed a positive constant bias of nearly 0.33 mmol/L (6 mg/dL). The Bland-Altman plots showed a positive mean difference of 0.43 mmol/L for results ≤5.55 mmol/L (≤100 mg/dL) and a positive mean percentage difference of 3.77% for results &gt;5.55 mmol/L (&gt;100 mg/dL), within the permissible deviation. The compliance values ranged from 76.0% to 90.3% for clinical concentration groups, with the highest compliance found between &gt;16.65–22.20 mmol/L (&gt;300–400 mg/dL). The Accu-Chek Inform II glucometers demonstrated in real-world reliability, with most results falling within acceptable risk categories. However, compliance still needs improvement, so manufacturers should assess opportunities for advancement.
DOI: 10.6084/m9.figshare.28445421.v1
title: Glucometer versus analyzer: comparable results with negligible clinical risk

description: This study assessed the reliability of Roche Accu-Chek Inform II glucometers in a real-world setting. A retrospective analysis was conducted on 6,695 paired results. Capillary samples were tested using Roche Accu-Chek Inform II glucometers, while venous samples were analyzed using Roche Cobas c503/702 analyzers. Compliance was assessed using modified criteria based on the ISO 15197 guideline and the CLSI EP09-A3 guideline using Passing-Bablok regression analysis, Bland-Altman plots, and Surveillance Error Grid (SEG) analysis. The overall compliance of glucometer results within ±15% or 0.83 mmol/L (15 mg/dL) of the reference method was 81.5%, below the acceptance criterion of 94.6%. SEG analysis showed that 90.3% of the paired results fell within the No-risk zone, with less than 0.001% in the moderate/lower-risk zone. The Emergency Department results indicated 87.8% overall compliance and 92.2% of pairs falling in the No-risk zone. Based on the regression analysis, the glucometer results showed a positive constant bias of nearly 0.33 mmol/L (6 mg/dL). The Bland-Altman plots showed a positive mean difference of 0.43 mmol/L for results ≤5.55 mmol/L (≤100 mg/dL) and a positive mean percentage difference of 3.77% for results &gt;5.55 mmol/L (&gt;100 mg/dL), within the permissible deviation. The compliance values ranged from 76.0% to 90.3% for clinical concentration groups, with the highest compliance found between &gt;16.65–22.20 mmol/L (&gt;300–400 mg/dL). The Accu-Chek Inform II glucometers demonstrated in real-world reliability, with most results falling within acceptable risk categories. However, compliance still needs improvement, so manufacturers should assess opportunities for advancement.
DOI: 10.15468/dl.rr7ds6
title: Occurrence Download

description: A dataset listing the 25 species recorded in GBIF matching the query:
{
 "and" : [
 "Country is France",
 "Geometry POLYGON((0.61452 47.69474,0.60824 47.68998,0.60318 47.68676,0.59897 47.6875,0.59741 47.68793,0.59398 47.6923,0.59222 47.69452,0.59151 47.6974,0.59385 47.69915,0.59339 47.70063,0.59222 47.7036,0.59142 47.70482,0.58997 47.70631,0.5863 47.70746,0.58479 47.70865,0.58287 47.711,0.58048 47.71238,0.58003 47.71081,0.57828 47.70934,0.57745 47.71,0.57591 47.70908,0.57472 47.709,0.57335 47.70851,0.57207 47.70874,0.56934 47.70951,0.56943 47.70799,0.56925 47.70653,0.56703 47.70635,0.56486 47.70529,0.56486 47.70305,0.56486 47.70032,0.56477 47.69894,0.56486 47.69794,0.56273 47.69776,0.55974 47.69679,0.5582 47.6959,0.55641 47.69547,0.55509 47.6948,0.55347 47.69288,0.55224 47.69022,0.55133 47.68777,0.54952 47.68594,0.54945 47.68406,0.55004 47.68271,0.55179 47.68249,0.55318 47.68294,0.5554 47.68165,0.55565 47.68072,0.55473 47.67767,0.55416 47.67625,0.55632 47.67541,0.55694 47.67417,0.55715 47.67257,0.55715 47.67098,0.5641 47.66976,0.57117 47.66862,0.57767 47.66968,0.57865 47.66769,0.5818 47.66879,0.58448 47.66915,0.58492 47.66863,0.58742 47.6693,0.58872 47.6706,0.59124 47.6709,0.59305 47.67207,0.59319 47.67266,0.59443 47.67216,0.59607 47.67284,0.59815 47.67476,0.59936 47.67587,0.60033 47.67738,0.60446 47.67813,0.60586 47.67849,0.60485 47.67946,0.60421 47.68082,0.60554 47.68111,0.60821 47.68136,0.60794 47.68262,0.61002 47.68262,0.61146 47.68219,0.61348 47.68269,0.61486 47.6829,0.61563 47.68762,0.61698 47.68733,0.61758 47.68922,0.61818 47.68918,0.61936 47.69103,0.61879 47.69135,0.61943 47.69243,0.61876 47.69257,0.61902 47.69345,0.6188 47.69409,0.61661 47.69397,0.61484 47.69415,0.61452 47.69474))",
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "PublishingOrg is 1928bdf0-f5d2-11dc-8c12-b8a03c50a862",
 "Year 2010-2025"
 ]
}

 The dataset's 25 records were derived from 8 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0002324-260120142942310/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.5281/zenodo.18234626
title: Dataset for A Unified Framework for Emergent Gravity: Entropic Hysteresis, Quantum Corrections, Dark Matter, Dark Energy, and Cosmological Implications

description: Datasets for vrifications of curves adn plots of the artcile "A Unified Framework for Emergent Gravity: Entropic Hysteresis, QuantumCorrections, Dark Matter, Dark Energy, and Cosmological Implications"
DOI: 10.7488/c6569c32-fb07-4754-8dcc-30d2a88f60da
title: Free-living dogs and public health in India: What are the connections between public debates and everyday people-dog interactions?

description: Preliminary research data for the purposes of ongoing knowledge exchange collaborations.
DOI: 10.6084/m9.figshare.27288512
title: Association between sleep disorders and preeclampsia: a systematic review and meta-analysis

description: Sleep disorders are prevalent during pregnancy and are associated with unfavorable outcomes. The meta-analysis evaluated the association between sleep disturbances and preeclampsia. We systematically searched in English and Persian databases, including Web of Science, Scopus, PubMed, ProQuest, Google Scholar, SID, IRANDOC, and MagIran, for studies published up to September 12, 2024. Eligibility was restricted to observational studies including cohort, case-control, and cross-sectional designs on expectant mothers diagnosed with preeclampsia and sleep disorders. The population studied comprised pregnant mothers with preeclampsia and diagnosed sleep disorders, diagnosed using polysomnography. The common sleep disorders investigated included insomnia, poor sleep quality, breathing problems, sleep apnea, and restless legs syndrome. Two authors independently reviewed and assessed the quality of the studies using the Newcastle-Ottawa Scale. Heterogeneity was evaluated using the I<sup>2</sup> statistic. Data were analyzed using RevMan 5, presenting results as random effects odds ratios (ORs) and standardized mean differences (SMDs), each with 95% confidence intervals (CIs). A total of 25 articles involving 3,992 participants were included in this analysis. Subgroup analysis showed that sleep disturbances significantly increased preeclampsia risk in pregnant women (Qualitative Sleep Disorder Indices OR = 6.79, 95% CI: 3.54–13.71; Quantitative Sleep Disorder Indices SMD = 3.91, 95% CI: 2.11–5.70, <i>p</i> &lt; 0.001). Although high heterogeneity was observed among studies on sleep disorders (I<sup>2</sup> = 82%, 96%), heterogeneity was low within studies focusing on sleep duration and quality (I<sup>2</sup> = 0%). The meta-analysis found significantly higher systolic (29.42 mmHg) and diastolic (16.67 mmHg) blood pressure, as well as increased BMI and maternal age, in the preeclampsia group compared to controls (<i>p</i> &lt; 0.01). Sleep disorders, including sleep-disordered breathing, obstructive sleep apnea, insomnia, and poor sleep quality, significantly increase the risk of developing preeclampsia. Prioritizing the diagnosis and treatment of these sleep disorders is crucial for improving pregnancy outcomes.
DOI: 10.6084/m9.figshare.27288512.v1
title: Association between sleep disorders and preeclampsia: a systematic review and meta-analysis

description: Sleep disorders are prevalent during pregnancy and are associated with unfavorable outcomes. The meta-analysis evaluated the association between sleep disturbances and preeclampsia. We systematically searched in English and Persian databases, including Web of Science, Scopus, PubMed, ProQuest, Google Scholar, SID, IRANDOC, and MagIran, for studies published up to September 12, 2024. Eligibility was restricted to observational studies including cohort, case-control, and cross-sectional designs on expectant mothers diagnosed with preeclampsia and sleep disorders. The population studied comprised pregnant mothers with preeclampsia and diagnosed sleep disorders, diagnosed using polysomnography. The common sleep disorders investigated included insomnia, poor sleep quality, breathing problems, sleep apnea, and restless legs syndrome. Two authors independently reviewed and assessed the quality of the studies using the Newcastle-Ottawa Scale. Heterogeneity was evaluated using the I<sup>2</sup> statistic. Data were analyzed using RevMan 5, presenting results as random effects odds ratios (ORs) and standardized mean differences (SMDs), each with 95% confidence intervals (CIs). A total of 25 articles involving 3,992 participants were included in this analysis. Subgroup analysis showed that sleep disturbances significantly increased preeclampsia risk in pregnant women (Qualitative Sleep Disorder Indices OR = 6.79, 95% CI: 3.54–13.71; Quantitative Sleep Disorder Indices SMD = 3.91, 95% CI: 2.11–5.70, <i>p</i> &lt; 0.001). Although high heterogeneity was observed among studies on sleep disorders (I<sup>2</sup> = 82%, 96%), heterogeneity was low within studies focusing on sleep duration and quality (I<sup>2</sup> = 0%). The meta-analysis found significantly higher systolic (29.42 mmHg) and diastolic (16.67 mmHg) blood pressure, as well as increased BMI and maternal age, in the preeclampsia group compared to controls (<i>p</i> &lt; 0.01). Sleep disorders, including sleep-disordered breathing, obstructive sleep apnea, insomnia, and poor sleep quality, significantly increase the risk of developing preeclampsia. Prioritizing the diagnosis and treatment of these sleep disorders is crucial for improving pregnancy outcomes.
DOI: 10.6084/m9.figshare.25762641
title: Prenatal diagnosis of chromosomal aberrations by chromosomal microarray analysis and pregnancy outcomes of fetuses with polyhydramnios

description: To explore the prenatal clinical utility of chromosome microarray analysis (CMA) for polyhydramnios and evaluate the short and long-term prognosis of fetuses with polyhydramnios. A total of 600 singleton pregnancies with persistent polyhydramnios from 2014 to 2020 were retrospectively enrolled in this study. All cases received amniocentesis and were subjected to CMA results. All cases were categorized into two groups: isolated polyhydramnios and non-isolated polyhydramnios [with soft marker(s) or with sonographic structural anomalies]. All fetuses were followed up from 6 months to five years after amniocentesis to acquire short and long-term prognosis. The detection rates of either aneuploidy or pathogenic copy number variants in fetuses with non-isolated polyhydramnios were significantly higher than those with isolated polyhydramnios (5.0 <i>vs.</i> 1.5%, <i>p</i> = 0.0243; 3.6 <i>vs.</i> 0.8%, <i>p</i> = 0.0288). The detection rate of total chromosomal abnormalities in the structural abnormality group was significantly higher than that in the isolated group (10.0 <i>vs.</i> 2.3%, <i>p</i> = 0.0003). In the CMA-negative cases, the incidence of termination of pregnancy, neonatal and childhood death, and non-neurodevelopmental disorders in fetuses combined with structural anomalies was significantly higher than that in fetuses with isolated polyhydramnios (<i>p</i> &lt; 0.05). We did not observe any difference in the prognosis between the isolated group and the combined group of ultrasound soft markers. In addition, the risk of postnatal neurodevelopmental disorders was also consistent among the three groups (1.6 <i>vs.</i> 1.3 <i>vs.</i> 1.8%). For low-risk pregnancies, invasive prenatal diagnosis of isolated polyhydramnios might be unnecessary. CMA should be considered for fetuses with structural anomalies. In CMA-negative cases, the prognosis of fetuses with isolated polyhydramnios was good, and polyhydramnios itself did not increase the risk of postnatal neurological development disorders. The worse prognosis mainly depends on the combination of polyhydramnios with structural abnormalities.
DOI: 10.6084/m9.figshare.25762641.v1
title: Prenatal diagnosis of chromosomal aberrations by chromosomal microarray analysis and pregnancy outcomes of fetuses with polyhydramnios

description: To explore the prenatal clinical utility of chromosome microarray analysis (CMA) for polyhydramnios and evaluate the short and long-term prognosis of fetuses with polyhydramnios. A total of 600 singleton pregnancies with persistent polyhydramnios from 2014 to 2020 were retrospectively enrolled in this study. All cases received amniocentesis and were subjected to CMA results. All cases were categorized into two groups: isolated polyhydramnios and non-isolated polyhydramnios [with soft marker(s) or with sonographic structural anomalies]. All fetuses were followed up from 6 months to five years after amniocentesis to acquire short and long-term prognosis. The detection rates of either aneuploidy or pathogenic copy number variants in fetuses with non-isolated polyhydramnios were significantly higher than those with isolated polyhydramnios (5.0 <i>vs.</i> 1.5%, <i>p</i> = 0.0243; 3.6 <i>vs.</i> 0.8%, <i>p</i> = 0.0288). The detection rate of total chromosomal abnormalities in the structural abnormality group was significantly higher than that in the isolated group (10.0 <i>vs.</i> 2.3%, <i>p</i> = 0.0003). In the CMA-negative cases, the incidence of termination of pregnancy, neonatal and childhood death, and non-neurodevelopmental disorders in fetuses combined with structural anomalies was significantly higher than that in fetuses with isolated polyhydramnios (<i>p</i> &lt; 0.05). We did not observe any difference in the prognosis between the isolated group and the combined group of ultrasound soft markers. In addition, the risk of postnatal neurodevelopmental disorders was also consistent among the three groups (1.6 <i>vs.</i> 1.3 <i>vs.</i> 1.8%). For low-risk pregnancies, invasive prenatal diagnosis of isolated polyhydramnios might be unnecessary. CMA should be considered for fetuses with structural anomalies. In CMA-negative cases, the prognosis of fetuses with isolated polyhydramnios was good, and polyhydramnios itself did not increase the risk of postnatal neurological development disorders. The worse prognosis mainly depends on the combination of polyhydramnios with structural abnormalities.
DOI: 10.15468/dl.jqwhs6
title: Occurrence Download

description: A dataset containing 0 species occurrences available in GBIF matching the query:
{"type":"and","predicates":[{"type":"within","geometry":"POLYGON ((101.333 1.534182, 101.262712 1.528614, 101.194156 1.512047, 101.12902 1.48489, 101.06891 1.44781, 101.015305 1.401723, 100.969525 1.347763, 100.932698 1.287258, 100.90573 1.221701, 100.889283 1.152704, 100.883763 1.081967, 100.889304 1.011231, 100.905769 0.942239, 100.932752 0.876688, 100.969589 0.8161929999999999, 101.015371 0.762243, 101.068973 0.716166, 101.129074 0.679095, 101.194195 0.651945, 101.262733 0.635383, 101.333 0.629816, 101.403267 0.635383, 101.471805 0.651945, 101.536926 0.679095, 101.597027 0.716166, 101.650629 0.762243, 101.696411 0.8161929999999999, 101.733248 0.876688, 101.760231 0.942239, 101.776696 1.011231, 101.782237 1.081967, 101.776717 1.152704, 101.76027 1.221701, 101.733302 1.287258, 101.696475 1.347763, 101.650695 1.401723, 101.59709 1.44781, 101.53698 1.48489, 101.471844 1.512047, 101.403288 1.528614, 101.333 1.534182))"},{"type":"equals","key":"CLASS_KEY","value":"212","matchCase":false},{"type":"greaterThanOrEquals","key":"YEAR","value":"2015","matchCase":false},{"type":"not","predicate":{"type":"in","key":"BASIS_OF_RECORD","values":["MATERIAL_CITATION","MATERIAL_SAMPLE","PRESERVED_SPECIMEN"],"matchCase":false}},{"type":"lessThanOrEquals","key":"COORDINATE_UNCERTAINTY_IN_METERS","value":"10000","matchCase":false},{"type":"equals","key":"LICENSE","value":"CC BY 4.0","matchCase":false}]}

 The dataset includes 0 records from 0 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0002333-260120142942310/datasets/export for details.
DOI: 10.6084/m9.figshare.27900849
title: A framework to classify gestational diabetes diagnosed by routine antenatal 75g glucose tolerance testing

description: To create an objective framework to classify gestational diabetes mellitus diagnosed by routine antenatal 75 g diabetes testing results to provide an alternative to current treatment-based classification. A framework was created to classify gestational diabetes according to the severity of glycemic abnormalities after routine antenatal 75 g GTT (classes 1 through 4, determined by fasting and post-test glycemic abnormalities). A retrospective cohort chart review was used to correlate clinically how often diet therapy alone maintained glycemic targets throughout pregnancy in each class. Chi-square analysis was used to assess inter-class differences in the success of diet therapy alone maintaining glycemic targets throughout pregnancy. Seventy-four of 228 (33%), 35/228 (15%), 76/228 (33%), and 43/228 (19%) of the study population were classified as Class 1, 2, 3, or 4, respectively. Of eighty-nine patients who maintained glycemic targets throughout pregnancy with diet alone 51/89 (57%) were Class 1, 20/89 (22.5%) were Class 2, 11/89 (12.5%) were Class 3, and 7/89 (8%) were Class 4. Chi-square analysis showed statistically significant inter-class differences in the likelihood of diet therapy alone maintaining glycemic targets throughout pregnancy. In this framework classifying gestational diabetes according to the severity of glycemic abnormalities after routine antenatal 75 g GTT (an objective proxy for disease severity), the higher the assigned class, the less likely that diet therapy alone maintained glycemic targets throughout pregnancy (a clinical proxy for disease severity).
DOI: 10.6084/m9.figshare.27900849.v1
title: A framework to classify gestational diabetes diagnosed by routine antenatal 75g glucose tolerance testing

description: To create an objective framework to classify gestational diabetes mellitus diagnosed by routine antenatal 75 g diabetes testing results to provide an alternative to current treatment-based classification. A framework was created to classify gestational diabetes according to the severity of glycemic abnormalities after routine antenatal 75 g GTT (classes 1 through 4, determined by fasting and post-test glycemic abnormalities). A retrospective cohort chart review was used to correlate clinically how often diet therapy alone maintained glycemic targets throughout pregnancy in each class. Chi-square analysis was used to assess inter-class differences in the success of diet therapy alone maintaining glycemic targets throughout pregnancy. Seventy-four of 228 (33%), 35/228 (15%), 76/228 (33%), and 43/228 (19%) of the study population were classified as Class 1, 2, 3, or 4, respectively. Of eighty-nine patients who maintained glycemic targets throughout pregnancy with diet alone 51/89 (57%) were Class 1, 20/89 (22.5%) were Class 2, 11/89 (12.5%) were Class 3, and 7/89 (8%) were Class 4. Chi-square analysis showed statistically significant inter-class differences in the likelihood of diet therapy alone maintaining glycemic targets throughout pregnancy. In this framework classifying gestational diabetes according to the severity of glycemic abnormalities after routine antenatal 75 g GTT (an objective proxy for disease severity), the higher the assigned class, the less likely that diet therapy alone maintained glycemic targets throughout pregnancy (a clinical proxy for disease severity).
DOI: 10.6084/m9.figshare.25833831
title: Treatment of cervical insufficiency and/or a short cervix with antimicrobial agents can restore cervical length and lead to pregnancy prolongation and term delivery

description: Treatment of cervical insufficiency and/or a short cervix with antimicrobial agents can restore cervical length and lead to pregnancy prolongation and term delivery
DOI: 10.6084/m9.figshare.25833831.v1
title: Treatment of cervical insufficiency and/or a short cervix with antimicrobial agents can restore cervical length and lead to pregnancy prolongation and term delivery

description: Treatment of cervical insufficiency and/or a short cervix with antimicrobial agents can restore cervical length and lead to pregnancy prolongation and term delivery